It is also suggested that FCM promotes secondary hepatic and lymphatic iFGF23 production without corresponding cleavage, leading to elevated circulating active FGF23 and further worsening hypophosphatemia [9]. This evidence concerns the gene FGF23 and hypophosphatemia.